[Not Yet Scheduled]
ChemioCare is a biotechnology company focused on improving the profiles of approved medicines by targeting and delivering therapeutic levels transdermally - to improve efficacy and safety. Our transdermal technology can deliver a precise therapeutic level to establish new indications or superior labels. Each product is rigorously selected to address a major medical unmet medical need of the approved active ingredient and can be developed via an accelerated regulatory path.

Our first program, CMIO-OLNZ, is designed to become the first product indicated for PARP inhibitor induced nausea and vomiting. Results for the Phase 1 proof of concept study expected Q1 2020, and expected to enter Phase 3 pivotal studies in ovarian cancer patients in 2020.

We are preparing for an IPO to fund Phase III and Phase II clinical studies for our lead programs. We intend to conduct a $70 M USD public offering in 2020, which includes a $20 M crossover round planned for the first quarter.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
CMIO-OLNZ, olanzapine 7-day transdermal patch
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Chairman and CEO